At a glance
- Originator Bristol-Myers Squibb
- Class Antiarrhythmics
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 21 Sep 2000 New profile
- 21 Sep 2000 Preclinical development for Arrhythmias in USA (Unknown route)